Milestone for Arana

By Dylan Bushell-Embling
Thursday, 02 October, 2008

Arana [ASX: ARA] has engineered an improved version of the VEGF-D antibody owned by Circadian Technologies [ASX: CIR] subsidiary Vegenics.

The antibody, designed to treat certain cancers, was modified into a humanised version using Arana's Superhumanisation technology.

It was then further refined using the company's EvoGene optimisation technology.

Conversion into humanised form will ensure that the risks of rejection of the treatment are minimised.

Circadian will shortly pay Arana milestone payments for the project, and Arana will be eligible to further milestone payments as the project advances through the various testing stages.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd